Pterostilbene-O-acetamidoalkylbenzylamines derivatives as novel dual inhibitors of cholinesterase with anti-β-amyloid aggregation and antioxidant properties for the treatment of Alzheimer’s disease
作者:Yuxing Li、Xiaoming Qiang、Yan Li、Xia Yang、Li Luo、Ganyuan Xiao、Zhongcheng Cao、Zhenghuai Tan、Yong Deng
DOI:10.1016/j.bmcl.2016.02.079
日期:2016.4
designed, synthesized and evaluated as dual inhibitors of AChE and BuChE. To further explore the multifunctional properties of the new derivatives, their antioxidant activities and inhibitory effects on self-induced Aβ1–42 aggregation and HuAChE-induced Aβ1–40 aggregation were also tested. The results showed that most of these compounds could effectively inhibit AChE and BuChE. Particularly, compound 21d
设计,合成和评价了一系列蝶形-O-乙酰氨基烷基苄胺,作为AChE和BuChE的双重抑制剂。为了进一步探索上自诱导Aβ的新衍生物,它们的抗氧化活性和抑制作用的多功能性质1 - 42聚集和胡胆碱酯酶诱导的Aβ 1 - 40聚合也进行了测试。结果表明,这些化合物大多数可以有效抑制AChE和BuChE。特别是化合物21d表现出最佳的AChE抑制活性(IC 50 = 0.06μM)和对BuChE的良好抑制作用(IC 50 = 28.04μM)。抑制动力学分析和分子模型研究均表明,这些化合物表现出混合型抑制作用,同时与AChE的CAS和PAS结合。除了抑制胆碱酯酶的活性,这些化合物还显示出不同水平的抗氧化剂活性。然而,这些新衍生物对自诱导和Hu AChE诱导的Aβ聚集的抑制活性不令人满意。考虑到生物学评估的结果,将设计进一步的修饰以增加对不同靶标的效力。这封信中显示的结果可能是进一步开发用于治疗阿尔茨海默氏病的多功能药物的新起点。